CIQUP/Departamento de Quimica e Bioquimica, Faculdade de Ciencias, Universidade do Porto, Porto 4169-007, Portugal.
Instituto de Investigaciones Biomedicas (IIB), Universidad de Las Americas, 170513 Quito, Ecuador.
Curr Neuropharmacol. 2017 Nov 14;15(8):1117-1135. doi: 10.2174/1570159X15666170116145316.
In the context of the current drug discovery efforts to find disease modifying therapies for Parkinson's disease (PD) the current single target strategy has proved inefficient. Consequently, the search for multi-potent agents is attracting more and more attention due to the multiple pathogenetic factors implicated in PD. Multiple evidences points to the dual inhibition of the monoamine oxidase B (MAO-B), as well as adenosine A2A receptor (A2AAR) blockade, as a promising approach to prevent the neurodegeneration involved in PD. Currently, only two chemical scaffolds has been proposed as potential dual MAO-B inhibitors/A2AAR antagonists (caffeine derivatives and benzothiazinones).
In this study, we conduct a series of chemoinformatics analysis in order to evaluate and advance the potential of the chromone nucleus as a MAO-B/A2AAR dual binding scaffold.
The information provided by SAR data mining analysis based on network similarity graphs and molecular docking studies support the suitability of the chromone nucleus as a potential MAOB/ A2AAR dual binding scaffold. Additionally, a virtual screening tool based on a group fusion similarity search approach was developed for the prioritization of potential MAO-B/A2AAR dual binder candidates. Among several data fusion schemes evaluated, the MEAN-SIM and MIN-RANK GFSS approaches demonstrated to be efficient virtual screening tools. Then, a combinatorial library potentially enriched with MAO-B/A2AAR dual binding chromone derivatives was assembled and sorted by using the MIN-RANK and then the MEAN-SIM GFSS VS approaches.
The information and tools provided in this work represent valuable decision making elements in the search of novel chromone derivatives with a favorable dual binding profile as MAOB inhibitors and A2AAR antagonists with the potential to act as a disease-modifying therapeutic for Parkinson's disease.
在当前寻找帕金森病(PD)疾病修饰疗法的药物发现努力中,单一靶点策略已被证明效率低下。因此,由于 PD 涉及多种发病因素,多效性药物的研究越来越受到关注。有多项证据表明,双重抑制单胺氧化酶 B(MAO-B)以及腺苷 A2A 受体(A2AAR)阻断,是预防 PD 相关神经退行性变的一种很有前途的方法。目前,仅提出了两种化学支架作为潜在的双重 MAO-B 抑制剂/A2AAR 拮抗剂(咖啡因衍生物和苯并噻嗪酮)。
在这项研究中,我们进行了一系列化学信息学分析,以评估和推进色酮核作为 MAO-B/A2AAR 双重结合支架的潜力。
基于网络相似性图的 SAR 数据挖掘分析和分子对接研究提供的信息支持色酮核作为潜在 MAOB/A2AAR 双重结合支架的适用性。此外,还开发了一种基于组融合相似性搜索方法的虚拟筛选工具,用于优先考虑潜在的 MAO-B/A2AAR 双重结合配体候选物。在所评估的几种数据融合方案中,MEAN-SIM 和 MIN-RANK GFSS 方法被证明是有效的虚拟筛选工具。然后,使用 MIN-RANK 和 THEN MEAN-SIM GFSS VS 方法对可能富含 MAO-B/A2AAR 双重结合色酮衍生物的组合文库进行组装和排序。
本工作提供的信息和工具为寻找具有有利双重结合特性的新型色酮衍生物提供了有价值的决策要素,这些衍生物可能作为帕金森病的疾病修饰治疗药物,同时抑制 MAO-B 和拮抗 A2AAR。